



King Pharmaceuticals, Inc.
Research and Development
CentreGreen Two, Suite 300
4000 CentreGreen Way
Cary, NC 27513

Eric G. Carter, PhD, MD
Chief Science Officer

June 4, 2008

Dear Healthcare Professional:

We would like to inform you that after careful consideration, King Pharmaceuticals[®], Inc. has decided to discontinue the manufacture of KEMADRIN[®] (procyclidine hydrochloride) tablets. KEMADRIN[®] tablets will remain available through pharmacies and wholesalers until current supplies are depleted. This decision is based upon many factors, including our understanding of current medical therapy and the availability of alternative therapies.

KEMADRIN[®] tablets are distributed through King Pharmaceuticals[®], Inc. No additional product will be available after King, pharmacy, and wholesaler supplies are exhausted.

If you have any questions or concerns, you may contact our Professional Information Services Department at 800-776-3637.

KEMADRIN[®] (procyclidine hydrochloride) is a synthetic antispasmodic compound indicated in the treatment of parkinsonism including the postencephalitic, arteriosclerotic, and idiopathic types. Partial control of the parkinsonism symptoms is the usual therapeutic accomplishment.

Important Safety Information:

KEMADRIN[®] tablets are contraindicated for use in angle-closure glaucoma although simple type glaucomas do not appear to be adversely affected. Anticholinergic effects can be produced by therapeutic doses; they include: dryness of the mouth, mydriasis, blurring of vision, giddiness, lightheadedness, and gastrointestinal disturbances such as nausea, vomiting, epigastric distress, and constipation. Occasionally an allergic reaction such as a skin rash may be encountered. Feelings of muscular weakness may occur. Acute suppurative parotitis as a complication of dry mouth has been reported.

Sincerely,

A handwritten signature in black ink that reads "Eric Carter".

Eric Carter, PhD, MD
Chief Science Officer

Please see accompanying full Prescribing Information.

KEMADRIN is a registered trademark of King Pharmaceuticals Research and Development, Inc., a wholly owned subsidiary of King Pharmaceuticals[®], Inc.